Reviva Pharmaceuticals Overview

  • Founded
  • 2006

Founded

  • Status
  • Public

  • Employees
  • 10

Employees

  • Stock Symbol
  • RVPH

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $4.90
  • (As of Friday Closing)

Reviva Pharmaceuticals General Information

Description

Reviva Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, respiratory, and metabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, 1) Brilaroxazine (RP5063) which is in clinical development and is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and 2) RP1208.

Contact Information

Website
www.revivapharma.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 19925 Stevens Creek Boulevard
  • Suite 100
  • Cupertino, CA 95014
  • United States
+1 (408) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Reviva Pharmaceuticals Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.90 $5.13 $1.56 - $9.25 22.7M 172K -$1.42

Reviva Pharmaceuticals Financials Summary

In Thousands,
USD 		TTM 30-Jun-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 122,143 63,690 7,568 113,566
Revenue 0 0 0 0
EBITDA (31,064) (24,501) (8,513) (2,434)
Net Income (30,679) (24,339) (8,522) (3,783)
Total Assets 11,842 18,924 31,404 8,762
Total Debt 222 0 373 1,964
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Reviva Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Reviva Pharmaceuticals‘s full profile, request access.

Request a free trial

Reviva Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Reviva Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company that discovers, develops, and seeks to co
Drug Discovery
Cupertino, CA
10 As of 2022
000.00
000000000 000.00

00000

mod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam,
0000 000000000
Washington, DC
000 As of 0000
00000
000000&0

000000

ugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in cu
0000000000000
Lexington, MA
00 As of 0000
00000
0000 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Reviva Pharmaceuticals Competitors (5)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vanda Pharmaceuticals Formerly VC-backed Washington, DC 000 00000 000000&0
0000000 0000000000 Corporate Backed or Acquired Lexington, MA 00 00000 000000&0 00000
000000 00000000000 Formerly VC-backed Boston, MA 000 00000 00000000 00000
00000000 Formerly VC-backed Dublin, Ireland 0000 00.000 000000000 00 00.000
0000000 0000000000 Corporation Vadodara, India 00000 00000 000000000 00000
You’re viewing 5 of 5 competitors. Get the full list »

Reviva Pharmaceuticals Patents

  • 101

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 8

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Reviva Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3749324-A1 Methods for treating pulmonary fibrosis Pending 28-Dec-2017 0000000000
US-20210128570-A1 Methods for treating pulmonary fibrosis Inactive 28-Dec-2017 000000000
US-20230061592-A1 Methods for treating pulmonary fibrosis Pending 28-Dec-2017 0000000000
EP-3749324-A4 Methods for treating pulmonary fibrosis Pending 28-Dec-2017 0000000000
EP-3244896-A4 Methods for treating pulmonary hypertension Pending 12-Jan-2015 A61K31/538 0
To view Reviva Pharmaceuticals’s complete patent history, request access »

Reviva Pharmaceuticals Executive Team (4)

Name Title Board Seat Contact Info
Laxminarayan Bhat Ph.D Chief Executive Officer & Board Member
Narayan Prabhu Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
You’re viewing 2 of 4 executive team members. Get the full list »

Reviva Pharmaceuticals Board Members (7)

Name Representing Role Since
Laxminarayan Bhat Ph.D Reviva Pharmaceuticals Chief Executive Officer & Board Member 000 0000
Les Funtleyder Self Board Member 000 0000
Peder Jensen MD Self Board Member 000 0000
Purav Patel Self Board Member 000 0000
You’re viewing 4 of 7 board members. Get the full list »

Reviva Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Reviva Pharmaceuticals Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 00000 14-Dec-2020 0000000000 Special Purpose Acquisition Company (SPAC) 000000000
To view Reviva Pharmaceuticals’s complete acquisitions history, request access »